Originally Posted by
MAC
The early NZ/Aus growth curve is a little different to the US curve IMHO, as PEB have been boldly attempting to sell concurrently with an R&D or pre-approvals development phase up until now.
If you or I were to sit in a senior urologists or a DHB general managers chair and spin around a few times we may very well realise that the last question we would want to receive is 'why we had committed to a CxBladder test programme that ultimately failed US regulatory approval'.
.
It is entirley possible that what we have been seeing in the second half of the 2013 year is health professionals waiting, waiting, waiting, waiting for CLIA approval, and now it’s been achieved it's now time for them to commit. The lull or anticipation period may be what we are seeing reflected in the local market FY13 sales figures having dropped slightly. And, sure enough we are only now, post CLIA approval, starting to see DHB's come on board.
Agree that the NZ, Australian and Spanish sales will be a nice sweetener on top of the US sales growth curve.
Ahemmm......., should any of the good folk at PEB ever read this thread, you’re most dedicated and loyal investors would like to request quarterly sales reports from here on forward, then we don't have to guess as above - many thanks.